FCH
KLDO

Freestone Capital Holdings’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Freestone Capital Holdings’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-500
Closed -$4.55K – 1250
2020
Q4 		$4.55K Hold
500
– – ﹤0.01% 1020
2020
Q3 		$5.54K Buy
+500
New +$3.46K ﹤0.01% 855

Other funds holding KLDO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Freestone Capital Holdings's KLDO Position: Q1 2021 in Review

Freestone Capital Holdings sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q1 2021, closing a stake of 500 shares — an estimated $4.55K sold.

Freestone Capital Holdings first reported a position in KLDO in Q3 2020 and held it in 2 quarters. The position peaked at $5.54K in Q3 2020. 71 funds tracked by Wall St. Rank hold KLDO as of Q1 2021.

  • Freestone Capital Holdings reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Freestone Capital Holdings sold 500 Kaleido Biosciences, Inc. Common Stock shares in Q1 2021, an estimated $4.55K.
  • Freestone Capital Holdings first reported a position in Kaleido Biosciences, Inc. Common Stock in Q3 2020 and held it in 2 quarters.
  • Freestone Capital Holdings's Kaleido Biosciences, Inc. Common Stock position peaked at $5.54K in Q3 2020.
  • 71 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q1 2021.

Based on Freestone Capital Holdings's 13F filing for Q1 2021, filed 17 May 2021.